This innovative study examines how leading pharmaceutical and biotech companies manage their key opinion leader (KOL) relationships. The study includes the following:

• Description of how various internal constituencies (sales reps, medical liaisons, clinical research associates, etc.) interact with KOLs
• Typical perks offered to KOLS
  • Research fees
  • Access to company data/resources
  • Other
• Trends in the relationship model, including impact of PhRMA guidelines and use of personnel beyond medical liaisons to interact with these individuals
• CRM software systems used with KOLs
• Key metrics utilized to evaluate KOL effectiveness
• Use of social influencing mapping to guide KOL tactical planning
• Honoraria levels for KOLs
  • National
  • Regional
  • Local